Dutch borderline panel established
This article was originally published in OTC Bulletin & The Rose Sheet
An expert advisory group has been set up in the Netherlands to advise the Dutch government on legislation covering so-called ‘borderline’ products, those products and substances which exist in a regulatory grey area between foods, medicines, cosmetics and biocides.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.